Last reviewed · How we verify
Placebo - dummy inhaler
A placebo inhaler delivers no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo effect.
A placebo inhaler delivers no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo effect. Used for Clinical trial control comparator (not a therapeutic indication).
At a glance
| Generic name | Placebo - dummy inhaler |
|---|---|
| Also known as | Placebo |
| Sponsor | University of Nottingham |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo inhalers are inert devices used as control comparators in clinical trials to measure the true efficacy of active medications against baseline and psychological expectation effects. They allow researchers to isolate the pharmacological benefit of a drug by accounting for patient expectation, symptom improvement from natural disease course, and other non-specific factors. The dummy inhaler is identical in appearance and use to active formulations but contains no therapeutic agent.
Approved indications
- Clinical trial control comparator (not a therapeutic indication)
Common side effects
Key clinical trials
- Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients (PHASE3)
- Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients With Stable Mild Asthma (NA)
- Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS). (PHASE2)
- Phase 4 COPD and Suboptimal Inspiratory Flow Rate (PHASE4)
- Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) of Macleods Pharmaceuticals Ltd (PHASE3)
- Study of Montelukast and Its Effect on Lower Leg Growth in Children With Asthma (MK-0476-254) (PHASE4)
- Usability of Levodopa Cyclops™ vs INBRIJA® in Parkinson's Patients
- Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |